

Special Issue

The Pathology of Biliary Tract Carcinoma (BTC)

Message from the Guest Editor

There are several controversial issues within the pathology of biliary tract carcinoma. While two subtypes of intrahepatic cholangiocarcinoma (small duct and large duct type) were proposed in the WHO's 2019 tumor classification, more studies and information are necessary to expand our understanding of their pathologic classification and characterization and the development of carcinoma. Several preinvasive lesions, such as IPNB and IOPN and ITPN and high-grade BillIN in the large bile ducts and pyloric gland adenoma, high-grade BillIN and ICPN in the gallbladder, were proposed in the WHO's 2019 tumor classification; however, more pathological and genetic/molecular studies are needed to help us to understand these lesions. More studies are mandatory for the clarification of the precursors to small duct intrahepatic cholangiocarcinoma. The peribiliary glands and the interface between hepatocytes and bile ductules are two anatomical regions that contain hepatic/biliary/enteric stem cells, and more pathologic studies and reviews are mandatory to reveal the neoplasms that arise in these stem cell niches.

Guest Editor

Dr. Yasuni Nakanuma

Department of Diagnostic Pathology, Shizuoka Cancer Center,
Shizuoka, Japan

Deadline for manuscript submissions

20 May 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/203737

Cancers

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)